VC-backed Pulmatrix touts inhaled drug tech's delivery of Advair

Pulmatrix, which has pulled in tens of millions in venture capital from blue chip backers, has shown in lab tests that its inhaled dry power drug tech called iSperse beat a typical formulation of GlaxoSmithKline's ($GSK) big-selling treatment Advair in delivering "an effective therapeutic dose." The Lexington, MA-based firm--which was co-founded by MIT bioengineer extraordinaire Bob Langer--said that the results of the experiments have helped it move forward with development of the inhaled delivery tech in a variety of disease such as cystic fibrosis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…